ESMO News

EMA Recommends Granting a Marketing Authorisation for Poherdy

noreply@esmo.org — Fri, 10 Apr 2026 07:04:00 +00:00

It is a biosimilar of pertuzumab which was authorised in the EU in 2013

Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers

noreply@esmo.org — Thu, 09 Apr 2026 07:04:00 +00:00

Findings from the real-world study conducted by the Netherlands Cancer Institute

FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

noreply@esmo.org — Wed, 08 Apr 2026 07:04:00 +00:00

Evidence for efficacy is based on the findings from the ROSELLA study

Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer

noreply@esmo.org — Tue, 07 Apr 2026 07:04:00 +00:00

Findings from the POLAR study

Nomination Process for the 2026 ESMO Society Awards Now Open

noreply@esmo.org — Tue, 07 Apr 2026 07:04:00 +00:00

The nomination process for the 2026 ESMO Society Awards is now open.

2026 ESMO Breast Cancer Award Recipient Announced

noreply@esmo.org — Tue, 07 Apr 2026 07:04:00 +00:00

ESMO announced today that the recipient of the 2026 ESMO Breast Cancer Award is Daniel F. Hayes, Stuart B. Padnos

NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable for Reaching High-Risk and Underserved Populations

noreply@esmo.org — Fri, 03 Apr 2026 07:04:00 +00:00

Results from publicly funded national lung cancer screening programme

EMA Recommends Extension of Therapeutic Indications for Asciminib

noreply@esmo.org — Fri, 03 Apr 2026 07:04:00 +00:00

New indication concerns treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase with the T315I mutation

ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at Work (PSR) as a Critical Opportunity to Protect the Wellbeing of the Cancer Workforce

noreply@esmo.org — Thu, 02 Apr 2026 12:04:00 +00:00

The EP’s recently published draft report on psychosocial risk, stress and mental health at work is a vital step forward in safeguarding the wellbeing of Europe’s health workforce, and the delivery of care to patients with cancer

Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline

noreply@esmo.org — Thu, 02 Apr 2026 08:04:00 +00:00

This ESMO–EURACAN CPG provides key recommendations for the diagnosis, staging, treatment and follow-up for uveal melanoma. It includes percutaneous hepatic perfusion and tebentafusp as treatment options for metastatic disease, reflecting emerging evidence with potential prognostic benefit.

Proton and Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer Show Similar Late Effects, QoL, Gastrostomy Dependence, Swallow Function, Local Control and OS

noreply@esmo.org — Thu, 02 Apr 2026 07:04:00 +00:00

Findings from the TORPEdO study

ESMO Welcomes Draft Report on Europe’s Beating Cancer Plan (BCP) Which Reflects Key Calls From the Society on Cancer Survivorship and Rare Cancers

noreply@esmo.org — Wed, 01 Apr 2026 07:04:00 +00:00

The BCP is an essential EU policy instrument for driving back cancer cases in Europe, accelerating cancer research, supporting cross-border clinical trials and ensuring that all patients with cancer receive high quality treatments.

FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma

noreply@esmo.org — Wed, 01 Apr 2026 07:04:00 +00:00

Evidence for efficacy is based on the results from the Study CA209-8UT (SWOG 1826)

Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer

noreply@esmo.org — Tue, 31 Mar 2026 07:03:00 +00:00

Findings from the ATOMIC study

Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type

noreply@esmo.org — Mon, 30 Mar 2026 08:03:00 +00:00

Findings from the Transplant Cancer Match Study

Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China

noreply@esmo.org — Fri, 27 Mar 2026 13:03:00 +00:00

New evidence from a Chinese cohort presented today at the European Lung Cancer Congress (ELCC) 2026 shows that onetime ‑lowdose computed tomography (LDCT) screening can significantly reduce lung cancer mortality in a non–risk‑ based population, including individuals with no smoking history.

EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib

noreply@esmo.org — Fri, 27 Mar 2026 09:03:00 +00:00

It is intended for the treatment of paediatric patients with low-grade glioma with BRAF alterations whose disease has progressed after one or more prior systemic therapies

Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia

noreply@esmo.org — Thu, 26 Mar 2026 09:03:00 +00:00

Findings from the RECITE study

FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

noreply@esmo.org — Wed, 25 Mar 2026 08:03:00 +00:00

Evidence for efficacy is based on the results from the MajesTEC-3 study

ESMO Calls for Cancer Care Integration in EU Global Health Resilience Initiative (GHRI)

noreply@esmo.org — Tue, 24 Mar 2026 08:03:00 +00:00